瑞格菲尼联合维替泊芬对肝癌细胞的影响  

Synergistic effect of regorafenib and verteporfin in hepatocellular carcinoma cells

作　　者：崔瑞文 朱曙光[1] 袁泽南 郑啟发 李华[1] 

机构地区：[1]中山大学附属第三医院肝脏外科,广州510630

出　　处：《中华实验外科杂志》2017年第12期2113-2115,共3页Chinese Journal of Experimental Surgery

基　　金：国家自然科学基金（81172038）

摘　　要：目的观察瑞格菲尼联合维替泊芬对肝癌细胞的影响。方法应用细胞计数试剂盒（CCK-8）法检测瑞格菲尼及瑞格菲尼联合维替泊芬对肝癌细胞增殖能力的影响，Transwell实验检测瑞格菲尼及瑞格菲尼联合维替泊芬对肝癌细胞迁移能力影响，Western blot法检测瑞格菲尼及瑞格菲尼联合维替泊芬对肝癌细胞上皮-间充质转化（EMT）相关蛋白表达的影响，流式细胞仪检测瑞格菲尼及瑞格菲尼联合维替泊芬对肝癌细胞凋亡影响。结果CCK-8实验结果表明瑞格菲尼联合维替泊芬（1 μmol/L）处理肝癌细胞的半数抑制浓度（IC50）为2.629 μmol/L，低于单用瑞格菲尼处理肝癌细胞的IC50（3.576 μmol/L）。Transwell检测结果显示瑞格菲尼（4 μmol/L）联合维替泊芬（2 μmol/L）组细胞迁移数为（147.00±9.54）个，低于瑞格菲尼（4 μmol/L）组细胞迁移数[（336.00±27.31）个，t＝－11.360，P＝0.000]，并且明显低于对照组细胞迁移数[（531.67±29.54）个，t＝－21.466，P＝0.000]。瑞格菲尼（2 μmol/L）联合维替泊芬（1 μmol/L）组的细胞凋亡率为（10.20±1.06）%，高于瑞格菲尼组细胞（2 μmol/L）的凋亡率[（5.13±0.95）%；t＝6.170，P＝0.004]，明显高于对照组细胞的凋亡率[（1.13±0.35）%；t＝14.080，P＝0.000]。结论维替泊芬能增强瑞格菲尼对肝癌细胞的抑制增殖、迁移，促进肝癌细胞凋亡的作用。ObjectiveTo investigate the synergistic effect of regorafenib and verteporfin in hepatocellular carcinoma cells.MethodsCell counting kit-8 （CCK-8） assay was used to detect the cytotoxicity of regorafenib and the combination of regorafenib and verteporfin. Transwell migration assay was used to detect cell migration ability of regorafenib and the combination of regorafenib and verteporfin. Western blotting was used to evaluate epithelial-mesenchymal transition （EMT） related protein of regorafenib and the combination of regorafenib and verteporfin. Flow cytometry was used to detected cell apoptosis of regorafenib and the combination of regorafenib and verteporfin.ResultsCCK-8 assay showed that the half maximal inhibitory concentration （IC50） of regorafenib was 3.576 μmol/L, and decreased to 2.629 μmol/L when regorafenib was combined with 1 μmol/L verteporfin. Transwell invasion assay showed that the membrane number of the cells treated with 4 μmol/L regorafenib and 2 μmol/L verteporfin was （147.00±9.54）, lower than the membrane number of the cells treated with 4 μmol/L regorafenib （336.00±27.31; t=-11.360, P=0.000）, and significantly lower than the membrane number in control group （531.67±29.54; t=-21.466, P=0.000）. The percentage of apoptotic cells treated with 1 μmol/L verteporfin and 2 μmol/L regorafenib was （10.20±1.06）%, higher than the percentage of apoptotic cells treated with 2 μmol/L regorafenib [（5.13±0.95）%; t=6.170, P=0.004], significantly higher than the percentage of apoptotic cells in control group [（1.13±0.35）%; t=14.080, P=0.000].ConclusionVerteporfin can enhance the effects of regorafenib on inhibiting proliferation and migration of hepatocellular carcinoma cells and promote the apoptosis of hepatocellular carcinoma cells.

关 键 词：肝癌 维替泊芬 瑞格菲尼 

分 类 号：R735.7[医药卫生—肿瘤]